Product Description
TMC310911 is a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) structurally closely related to darunavir (DRV) but with improved virological characteristics. TMC310911 has potent activity against wild-type (WT) HIV-1 (median 50% effective concentration [EC50], 14 nM) and a wide spectrum of recombinant HIV-1 clinical isolates, including multiple-PI-resistant strains with decreased susceptibility to currently approved PIs (fold change [FC] in EC50, >10). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232804/)
Mechanisms of Action: HIV Protease Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: HIV Infections|Acquired Immunodeficiency Syndrome
Phase 1: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2008-008190-58 | P2 |
Completed |
HIV Infections |
2011-02-21 |
|
| PEPI-TiDP23-C103 | P1 |
Completed |
HIV Infections |
2009-10-01 |
|
| CR015952 | P2 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections |
2009-08-01 |